CoChat

An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy

Striano, P., Coppola, A., Pezzella, M., Ciampa, C., Specchio, N., Ragona, F., Mancardi, M. M., Gennaro, E., Beccaria, F., Capovilla, G., Rasmini, P., Besana, D., Coppola, G. G., Elia, M., Granata, T., Vecchi, M., Vigevano, F., Viri, M., Gaggero, R., Striano, S., Zara, F. · 2007 · Neurology
Cited by 116

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To conduct an open-label, add-on trial on safety and efficacy of levetiracetam in severe myoclonic epilepsy of infancy (SMEI). PATIENTS AND METHODS: SMEI patients were recruited from different centers according to the following criteria: age > or =3 years; at least four tonic-clonic seizures/month during the last 8 weeks; previous use of at least two drugs. Levetiracetam was orally administrated at starting dose of approximately 10 mg/kg/day up to 50 to 60 mg/kg/day in two doses. Treatment period included a 5- to 6-week up-titration phase and a 12-week evaluation phase. Efficacy variables were responder rate by seizure type and reduction of the mean number per week of each seizure type. Analysis was performed using Fisher exact and Wilcoxon tests. RESULTS: Twenty-eight patients (mean age: 9.4 +/- 5.6 years) entered the study. Sixteen (57.1%) showed SCN1A mutations. Mean number of concomitant drugs was 2.5. Mean levetiracetam dose achieved was 2,016 mg/day. Twenty-three (82.1%) completed the trial. Responders were 64.2% for tonic-clonic, 60% for myoclonic, 60% for focal, and 44.4% for absence seizures. Number per week of tonic-clonic (median: 3 vs 1; p = 0.0001), myoclonic (median: 21 vs 3; p = 0.002), and focal seizures (median: 7.5 vs 3; p = 0.031) was significantly decreased compared to baseline. Levetiracetam effect was not related to age at onset and duration of epilepsy, genetic status, and concomitant therapy. Levetiracetam was well tolerated by subjects who completed the study. To date, follow-up ranges 6 to 36 months (mean, 16.2 +/- 13.4). CONCLUSION: Levetiracetam add-on is effective and well tolerated in severe myoclonic epilepsy of infancy. Placebo-controlled studies should confirm these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000265222.24102.db

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 116

Metadata

Authors
Striano, P., Coppola, A., Pezzella, M., Ciampa, C., Specchio, N., Ragona, F., Mancardi, M. M., Gennaro, E., Beccaria, F., Capovilla, G., Rasmini, P., Besana, D., Coppola, G. G., Elia, M., Granata, T., Vecchi, M., Vigevano, F., Viri, M., Gaggero, R., Striano, S., & Zara, F.
Venue
Neurology
Published
2007-07-17
Volume
69
Issue
3
Pages
250-254
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1992787503
Cited by
116
References
3
FWCI
6.01
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. https://app.cochat.ai/papers/10.1212/01.wnl.0000265222.24102.db
The paper
Striano, P., Coppola, A., Pezzella, M., Ciampa, C., Specchio, N., Ragona, F., Mancardi, M. M., Gennaro, E., Beccaria, F., Capovilla, G., Rasmini, P., Besana, D., Coppola, G. G., Elia, M., Granata, T., Vecchi, M., Vigevano, F., Viri, M., Gaggero, R., . . . Zara, F. (2007). An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. https://doi.org/10.1212/01.wnl.0000265222.24102.db

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.